{"schema_version":"secwatch.filing_event.v1","accession":"0001743881-26-000026","form_type":"8-K","ticker":"BBIO","cik":"0001743881","company_name":"BridgeBio Pharma, Inc.","filed_at":"2026-08-10T20:03:45+00:00","discovered_at":"2026-08-10T20:05:01.445787+00:00","generated_at":"2026-08-10T20:05:19.294292+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"BridgeBio Q2 revenue $243.7M, Attruby $222.4M; net loss $152.2M","bullets":["Q2 total revenue $243.7M vs $110.6M YoY; US Attruby net product revenue $222.4M.","Net loss attributable to common stockholders $152.2M ($0.78/share) vs $181.9M ($0.95) year-ago.","Cash and marketable securities $720.2M at Jun 30; $1B preferred equity closed Jul 1 led by Sixth Street.","NDAs: BBP-418 PDUFA Nov 27 2026 (Priority Review), encaleret May 8 2027, infigratinib submitted.","Real-world data: acoramidis 37% reduction in composite CV events vs tafamidis (TriNetX, p=0.002)."],"urls":{"canonical":"https://secwatch.observer/filing/0001743881-26-000026","json":"https://secwatch.observer/filing/0001743881-26-000026.json","markdown":"https://secwatch.observer/filing/0001743881-26-000026.md","text":"https://secwatch.observer/filing/0001743881-26-000026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1743881/000174388126000026/0001743881-26-000026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1743881/000174388126000026/bbio-20260810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-10T20:05:19.294292+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}